Business Plan · Confidential
Ninti Hospital
Business Plan
Business Plan
Five-year network roadmap to ~1,000 beds across six facilities, detailed Delhi NCR flagship project execution, oncology-focused clinical model, market positioning, growth strategy, and risk framework. Confidential — authorized investors only.
Strategic Targets
Total Beds by 2029~1,000
Facilities8 (Bihar · UP · Delhi NCR)
Y3 Flagship EBITDA Margin19%
Y10 Flagship EBITDA Margin41%
Y10 Flagship PAT Margin30%
Occupancy Target (Y5)77% (230 beds / 300 census)
01
Strategy
The Ninti Playbook — Specialty-First Network
Ninti's growth strategy differs from conventional multi-specialty hospital chains: instead of building large general hospitals in capital cities first, Ninti is building specialty depth in underserved markets first, then using that brand credibility to enter premium markets with super-specialty positioning. The sequence:
- Phase 1 (Operational) — Single-super-specialty cardiac centres in tier-2/3 Bihar (Saharsa, Muzaffarpur). Proof points: both broke even within 6 months.
- Phase 2 (Infra Ready / Under Build) — Patna Mother Care (100 beds), Begusarai Multi-Specialty (175 beds, 9 specialties including cardiac/neuro/gastro/ortho), Purnea Cardiac (100 beds, 2026).
- Phase 3 (Site Identified / Acquired) — Patna Multispecialty (200 beds, 2027), Lucknow Multispecialty (200 beds, 2027).
- Phase 4 (Flagship) — Delhi NCR Onco-focused Super-Specialty Hospital (350 beds, 2029). The apex of the model.
02
Market Validation
Cardiac Centre Performance — Ground Truth
The cardiac-centre economics have been validated on the ground over 6 months:
| Centre | Apr-24 | May-24 | Jun-24 | Jul-24 | Aug-24 | Sep-24 |
|---|---|---|---|---|---|---|
| Saharsa — Revenue / Expense (INR Lakhs) | ||||||
| Revenue | 22 | 21 | 17 | 26 | 25 | 45 |
| Expense | 26 | 27 | 26 | 28 | 28 | 33 |
| Status | - | - | - | - | - | Breakeven |
| Muzaffarpur — Revenue / Expense (INR Lakhs) | ||||||
| Revenue | - | - | 1 | 3 | 5 | 19 |
| Expense | 9 | 18 | 14 | 18 | 17 | 19 |
| Status | Pre-op | Pre-op | - | - | - | Breakeven |
Why This Matters for Delhi NCR
The cardiac-centre breakeven trajectory — consistent revenue ramp + disciplined expense management — de-risks the Delhi NCR flagship by demonstrating the management team's ability to commission, commercialise, and operate specialty healthcare assets on schedule. The Delhi NCR super-specialty project is larger and more complex, but the operating DNA has been tested.
03
Delhi NCR Execution
30-Month Build · Specialty-Stacked Facility
| Milestone | Timeline | Gate |
|---|---|---|
| Construction Period | 30 months | C1 / C2 / C3 loan tranches |
| Loan Disbursement C1 | Construction start | INR 33.80 Cr |
| Loan Disbursement C2 | Mid-build | INR 67.60 Cr |
| Loan Disbursement C3 | Pre-commissioning | INR 67.60 Cr |
| Loan Disbursement Y1 (Opex/WC) | Post-commissioning | INR 50.00 Cr |
| Total Loan | — | INR 218.85 Cr |
| Commercial Operation Date (COD) | Month 31 | Revenue generation begins |
Specialty Mix & Clinical Model
The Delhi NCR facility is structured around four super-specialty verticals with oncology as the primary anchor:
- Oncology (Anchor) — Surgical Oncology, Medical Oncology, Radiation Oncology, Gynae Oncology, BMT, Diagnostic Imaging, Infusion Centres, Image-Guided Radiotherapy.
- Cardiology — Full cardiac diagnostics, cath lab, CTVS OT, cardiac ICU.
- Neurology — Neuro-intervention, neurosurgery, stroke care.
- Orthopaedics — Joint replacement, spine surgery, trauma.
Clinical leadership: Dr. Rajesh Jain (Director Onco-sciences, 25+ years, DNB Surgical Oncology RGCI), Dr. Shruti Bhatia (Principal Gynae Oncology, 20+ years, MAMC/Kasturba/Tata Memorial training), Dr. Ishan Mohan (Consultant Surgical Oncology, MCh Tata Memorial), Dr. Pranjal Kulshreshtha (Consultant Surgical Oncology, DNB Army Hospital). All currently at Action Cancer Hospital — a credible cluster onboarding.
04
Unit Economics
Revenue Model · Bed Utilisation · Ramp
| Operating Metric | Y1 | Y2 | Y3 | Y4 | Y5 | Y10 |
|---|---|---|---|---|---|---|
| Total Bed Strength | 300 | 300 | 300 | 300 | 300 | 300 |
| Census Beds | 270 | 270 | 270 | 270 | 270 | 270 |
| Avg Occupied Beds / Day | 68 | 122 | 162 | 203 | 230 | 270 |
| Occupancy Rate | 25% | 45% | 60% | 75% | 85% | 100% |
| Avg Revenue / Occupied Bed / Day (INR) | 59,650 | 71,580 | 80,170 | 88,988 | 97,887 | 1,37,232 |
Revenue Mechanics
The model assumes a dual lever: occupancy ramp from 25% (Y1) to 85% (Y5), plus ARPOB growth from INR 60K/day to INR 97K/day over the same period. Both are plausible for an onco-focused super-specialty facility: oncology commands premium procedure pricing, and the Delhi NCR catchment supports occupancy ramp even with conservative demand assumptions. Y10 ARPOB of INR 1.37L/day reflects consistent 7-8% annual price escalation plus mix shift to higher-acuity procedures.
05
Cost Structure
Direct + Indirect Cost Profile
| Cost Line (% of Revenue) | Y1 | Y2 | Y3 | Y5 | Y7 | Y10 |
|---|---|---|---|---|---|---|
| Direct Costs (Cost of Goods Sold) | ||||||
| Consumables | 25% | 25% | 24% | 23% | 22% | 20% |
| Doctor Fees | 20% | 20% | 19% | 18% | 17% | 16% |
| Partner Sharing (Lease) | 8% | 5% | 5% | 5% | 5% | 5% |
| Total Direct Cost | 53% | 49% | 48% | 46% | 44% | 40% |
| Gross Contribution | 47% | 51% | 52% | 54% | 56% | 60% |
| Indirect Costs | ||||||
| Personnel | 28% | 17% | 14% | 10% | 10% | 9% |
| General Admin | 23% | 16% | 12% | 8% | 7% | 6% |
| Selling & Marketing | 18% | 10% | 7% | 4% | 3% | 3% |
| Total Indirect Cost | 69% | 43% | 33% | 22% | 20% | 19% |
| EBITDA Margin | -23% | 8% | 19% | 32% | 36% | 41% |
06
Risk Framework
Identified Risks & Mitigants
HIGHER
Doctor and clinical staff retention
Mitigant: Clinical leaders (Dr. Jain, Dr. Bhatia, Dr. Mohan, Dr. Kulshreshtha) already have 20–25 years' vintage at Action Cancer, RGCI, Tata Memorial, and BL Kapoor. Founding team's goodwill enables onboarding. Training, webinars, workshops, and digital CME access retention programs.
MEDIUM
Construction delays / approvals / licensing
Mitigant: 30-month construction window has contingency. Senior Biomedical Engineer (Mr. Dagar) leads equipment planning and optimised procurement with 20+ years' experience. HIS commissioning under Dr. Sanjeev Baisla (20+ years digital-transformation).
MEDIUM
Competition from entrenched Delhi NCR super-specialty players
Mitigant: Onco focus differentiates from general multi-specialty competitors. Rising Delhi NCR cancer incidence (+23% by 2026) supports multi-player market expansion. Patient-first, personalised-treatment positioning targets under-served premium segment.
MEDIUM
Price caps on consumables / government regulation
Mitigant: Specialised oncology procedures are less exposed to consumable-price caps than high-volume general procedures. Patient mix designed for insurance and cash-pay with medical-tourism overlay.
LOWER
Equipment downtime affecting revenue
Mitigant: Senior biomedical engineering function plans redundancy and service-contract coverage for mission-critical equipment (MRI, CT, linear accelerator, PET-CT).
Full financial model
10-year P&L, balance sheet, cash flow, working capital, and loan schedule available under separate password.
Disclaimer · Confidential Business Plan
Strictly Confidential
This Business Plan is confidential and intended for the exclusive use of the authorised recipient. It contains forward-looking statements subject to risks and uncertainties; actual results may differ materially. Investment involves significant risk, including the risk of loss of principal.
Ninti Hospital · www.nintihospital.com · info@nintihospital.com
Ninti Hospital · www.nintihospital.com · info@nintihospital.com